intravenous immune globulin

DRUG5 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, Loma Linda University, National Taiwan University Hospital, Seoul National University Hospital, Instituto Grifols, S.A.

Conditions

COVID-19End Stage Renal DiseaseKidney TransplantationPlasmapheresisPompe DiseaseRenal Transplant

Phase 2

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

CompletedNCT04432324

Instituto Grifols, S.A.COVID-19

Start: 2020-06-02End: 2021-03-03Updated: 2021-03-10

Phase 4

Immune Modulation Therapy for Pompe Disease

National Taiwan University HospitalPompe Disease

Start: 2015-08-31End: 2020-07-31Target: 8Updated: 2016-04-15

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

CompletedNCT04033276

Seoul National University HospitalRenal Transplant

Start: 2019-01-08End: 2022-05-03Updated: 2022-10-26

Unknown Phase

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

WithdrawnNCT00203281

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityKidney Transplantation, Plasmapheresis

Start: 2003-02-28End: 2009-09-30Updated: 2016-10-21

Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients

TerminatedNCT00586716

Loma Linda UniversityEnd Stage Renal Disease

Start: 2004-11-30End: 2009-10-31Updated: 2017-01-09

Related Papers

Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy

Frontiers in Immunology2024-04-2314 citations

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients

Scientific Reports2023-05-115 citations